Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Auranofin
Drug ID BADD_D00191
Description Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.
Indications and Usage Used in the treatment of active, progressive or destructive forms of inflammatory arthritis, such as adult rheumatoid arthritis.
Marketing Status approved; investigational
ATC Code M01CB03
DrugBank ID DB00995
KEGG ID D00237
MeSH ID D001310
PubChem ID 24199313
TTD Drug ID D0L2UN
NDC Product Code 54766-093; 49812-0067
UNII 3H04W2810V
Synonyms Auranofin | Ridaura | SK&F D 39162 | SK&F-39162 | SK&F 39162 | SK&F39162 | Crisinor | Ridauran
Chemical Information
Molecular Formula C20H34AuO9PS
CAS Registry Number 34031-32-8
SMILES CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001--Not Available
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Angioedema23.04.01.001; 10.01.05.009; 22.04.02.008--Not Available
Aplasia pure red cell10.02.01.003; 01.03.03.001--Not Available
Aplastic anaemia01.03.03.002--Not Available
Colitis ulcerative10.02.01.004; 07.08.01.005--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Corneal deposits06.06.03.002--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diarrhoea07.02.01.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Eosinophilia01.02.04.001--
Eye disorder06.08.03.001--Not Available
Flatulence07.01.04.002--
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009--Not Available
Gastrointestinal pain07.01.05.005--
Gingivitis07.09.10.002; 11.01.04.013--
Glomerulonephritis membranous20.05.01.007--Not Available
Glossitis07.14.01.001--Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Lenticular opacities06.06.01.003--Not Available
Leukopenia01.02.02.001--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene